By Josh White
Date: Wednesday 25 Jun 2025
(Sharecast News) - Scancell announced on Wednesday that it has started dosing patients in cohort four of its phase 2 'SCOPE' clinical trial, evaluating the intradermal administration and accelerated dosing of its iSCIB1+ immunotherapy for advanced unresectable melanoma.
By Benjamin Chiou
Date: Wednesday 12 Jun 2024
(Sharecast News) - Scancell Holdings saw shares surge on Wednesday after the the AIM-listed oncology immunotherapies group announced an agreement with a "major international biotechnology company".
By Josh White
Date: Tuesday 29 Aug 2023
(Sharecast News) - Immunotherapy developer Scancell announced the appointment of Sath Nirmalananthan as its new chief financial officer on Tuesday, effective immediately.
Currency | UK Pounds |
Share Price | 10.25p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 19.50 |
52 Week Low | 7.50 |
Volume | 276,904 |
Shares Issued | 1,036.78m |
Market Cap | £106.27m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
Strong Buy | 1 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
15:42 | 66,240 @ 10.18p |
14:41 | 383 @ 9.75p |
14:02 | 20 @ 9.75p |
12:50 | 321 @ 10.18p |
11:40 | 52,336 @ 10.20p |
CFO | Sath Nirmalananthan |
CEO | Phil L'Huillier |
You are here: research